Pulmonary sarcomatoid carcinomas: A practical overview

Research output: Contribution to journalArticle

Abstract

Pulmonary sarcomatoid carcinomas (PSCs) are currently defined as poorly differentiated non-small-cell carcinomas containing a component with sarcoma or sarcoma-like (spindle and/or giant cell) features. They consist of 5 major histological variants, namely pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma. The segregation of PSCs into a distinct clinicopathologic entity seems justified on the basis of morphologic, behavioral, and genotypic/phenotypic attributes. As a group, PSCs generally run an aggressive clinical course and may cause major difficulties in the differential diagnosis with other primary and secondary malignancies of the lung. At present, PSCs are believed to represent a family of carcinomas "in transition"in which diverse pathways of clonal evolution account for histological differences of a common ancestor lesion. The sarcomatous or sarcomatoid component of these tumors is thought to derive from carcinoma cells during the progression of carcinogenesis through the activation of an epithelial-mesenchymal transition program leading to sarcomatous transformation or metaplasia (conversion paradigm). Conceivably, targeting the epithelial-mesenchymal transition program could become a valid therapeutic strategy for these life-threatening tumors, whose sensitivity to current medical manipulation is disappointing.

Original languageEnglish
Pages (from-to)103-120
Number of pages18
JournalInternational Journal of Surgical Pathology
Volume18
Issue number2
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Carcinoma
Lung
Epithelial-Mesenchymal Transition
Sarcoma
Pulmonary Blastoma
Giant Cell Carcinoma
Clonal Evolution
Carcinosarcoma
Neoplasms
Metaplasia
Giant Cells
Carcinogenesis
Differential Diagnosis

Keywords

  • Carcinoma
  • Epithelial
  • Lung
  • Mesenchymal
  • Sarcomatoid
  • Survival
  • Transition

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

@article{f94e77f71d5a48eabe79c872c2b13833,
title = "Pulmonary sarcomatoid carcinomas: A practical overview",
abstract = "Pulmonary sarcomatoid carcinomas (PSCs) are currently defined as poorly differentiated non-small-cell carcinomas containing a component with sarcoma or sarcoma-like (spindle and/or giant cell) features. They consist of 5 major histological variants, namely pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma. The segregation of PSCs into a distinct clinicopathologic entity seems justified on the basis of morphologic, behavioral, and genotypic/phenotypic attributes. As a group, PSCs generally run an aggressive clinical course and may cause major difficulties in the differential diagnosis with other primary and secondary malignancies of the lung. At present, PSCs are believed to represent a family of carcinomas {"}in transition{"}in which diverse pathways of clonal evolution account for histological differences of a common ancestor lesion. The sarcomatous or sarcomatoid component of these tumors is thought to derive from carcinoma cells during the progression of carcinogenesis through the activation of an epithelial-mesenchymal transition program leading to sarcomatous transformation or metaplasia (conversion paradigm). Conceivably, targeting the epithelial-mesenchymal transition program could become a valid therapeutic strategy for these life-threatening tumors, whose sensitivity to current medical manipulation is disappointing.",
keywords = "Carcinoma, Epithelial, Lung, Mesenchymal, Sarcomatoid, Survival, Transition",
author = "Giuseppe Pelosi and Angelica Sonzogni and {De Pas}, Tommaso and Domenico Galetta and Giulia Veronesi and Lorenzo Spaggiari and Michela Manzotti and Caterina Fumagalli and Enrica Bresaola and Oscar Nappi and Giuseppe Viale and Juan Rosai",
year = "2010",
month = "4",
doi = "10.1177/1066896908330049",
language = "English",
volume = "18",
pages = "103--120",
journal = "International Journal of Surgical Pathology",
issn = "1066-8969",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Pulmonary sarcomatoid carcinomas

T2 - A practical overview

AU - Pelosi, Giuseppe

AU - Sonzogni, Angelica

AU - De Pas, Tommaso

AU - Galetta, Domenico

AU - Veronesi, Giulia

AU - Spaggiari, Lorenzo

AU - Manzotti, Michela

AU - Fumagalli, Caterina

AU - Bresaola, Enrica

AU - Nappi, Oscar

AU - Viale, Giuseppe

AU - Rosai, Juan

PY - 2010/4

Y1 - 2010/4

N2 - Pulmonary sarcomatoid carcinomas (PSCs) are currently defined as poorly differentiated non-small-cell carcinomas containing a component with sarcoma or sarcoma-like (spindle and/or giant cell) features. They consist of 5 major histological variants, namely pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma. The segregation of PSCs into a distinct clinicopathologic entity seems justified on the basis of morphologic, behavioral, and genotypic/phenotypic attributes. As a group, PSCs generally run an aggressive clinical course and may cause major difficulties in the differential diagnosis with other primary and secondary malignancies of the lung. At present, PSCs are believed to represent a family of carcinomas "in transition"in which diverse pathways of clonal evolution account for histological differences of a common ancestor lesion. The sarcomatous or sarcomatoid component of these tumors is thought to derive from carcinoma cells during the progression of carcinogenesis through the activation of an epithelial-mesenchymal transition program leading to sarcomatous transformation or metaplasia (conversion paradigm). Conceivably, targeting the epithelial-mesenchymal transition program could become a valid therapeutic strategy for these life-threatening tumors, whose sensitivity to current medical manipulation is disappointing.

AB - Pulmonary sarcomatoid carcinomas (PSCs) are currently defined as poorly differentiated non-small-cell carcinomas containing a component with sarcoma or sarcoma-like (spindle and/or giant cell) features. They consist of 5 major histological variants, namely pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma. The segregation of PSCs into a distinct clinicopathologic entity seems justified on the basis of morphologic, behavioral, and genotypic/phenotypic attributes. As a group, PSCs generally run an aggressive clinical course and may cause major difficulties in the differential diagnosis with other primary and secondary malignancies of the lung. At present, PSCs are believed to represent a family of carcinomas "in transition"in which diverse pathways of clonal evolution account for histological differences of a common ancestor lesion. The sarcomatous or sarcomatoid component of these tumors is thought to derive from carcinoma cells during the progression of carcinogenesis through the activation of an epithelial-mesenchymal transition program leading to sarcomatous transformation or metaplasia (conversion paradigm). Conceivably, targeting the epithelial-mesenchymal transition program could become a valid therapeutic strategy for these life-threatening tumors, whose sensitivity to current medical manipulation is disappointing.

KW - Carcinoma

KW - Epithelial

KW - Lung

KW - Mesenchymal

KW - Sarcomatoid

KW - Survival

KW - Transition

UR - http://www.scopus.com/inward/record.url?scp=77949881940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949881940&partnerID=8YFLogxK

U2 - 10.1177/1066896908330049

DO - 10.1177/1066896908330049

M3 - Article

C2 - 19124452

AN - SCOPUS:77949881940

VL - 18

SP - 103

EP - 120

JO - International Journal of Surgical Pathology

JF - International Journal of Surgical Pathology

SN - 1066-8969

IS - 2

ER -